课题基金 / 基金详情

Use of post-acute care and outcomes among Medicare Advantage and fee-for-service beneficiaries

Use of post-acute care and outcomes among Medicare Advantage and fee-for-service beneficiaries
Medicare Advantage 和按服务收费受益人对急性后护理的使用和结果
批准号:
10659109
负责人:
Robert Edward Burke
金额:
$36.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2025-06-30

项目摘要

项目成果

Robert Edward Burke的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary Post-acute care (PAC) is common, and costly, and may not lead to optimal health outcomes for older adults. However, it is unknown how to improve outcomes and/or lower costs, or value, of PAC. More than 40% of Medicare fee-for-service (FFS) beneficiaries receive PAC after hospitalization, predominantly in skilled nursing facilities (SNFs) and by home health (HH) agencies, at a cost of more than $60 billion annually. Unfortunately, around 1 in 4 is readmitted to the hospital within 30 days of discharge to PAC, and nearly half of beneficiaries in SNF fail to return to the community within 100 days of hospital discharge. The rapid expansion of Medicare Advantage (MA) provides an opportunity to evaluate a different approach to PAC utilization. More than one- third of all Medicare beneficiaries are now enrolled in Medicare Advantage (MA) plans, which receive capitated payments and take financial risk for the care needs of beneficiaries. MA plan directors confirm in interviews that PAC is a major focus of efforts to reduce care utilization and costs through four mechanisms: limiting use of PAC overall; steering beneficiaries to less expensive forms (HH) instead of more expensive forms (SNF); restricting choice of providers; and limiting PAC length of stay. Early reports suggest MA plans may strongly influence PAC utilization. Whether reductions in PAC utilization in MA improve PAC value is unknown. The limited existing literature has two main gaps: first, it does not adequately account for the substantial underlying differences in the MA and FFS populations. Second, it has focused on short-term outcomes, while PAC likely has a substantial impact on longer-term functional status and independence. Our overall goal is to inform patients, providers, and policymakers about ways to improve the value of PAC for all Medicare beneficiaries. To achieve this goal, we propose innovative analytic strategies that address limitations in the prior literature and allow accurate assessment of the use and outcomes of PAC in similar MA and FFS beneficiaries. Our aims are to: 1) Compare use of SNF and HH in similar MA and FFS beneficiaries after hospital discharge, and the impact of different mechanisms for limiting PAC utilization; 2) Compare PAC outcomes (community days, long-term institutionalization, rehospitalization, mortality) at 100 days and 1 year after hospital discharge in MA and FFS; and 3) Evaluate the effects of MA versus FFS enrollment on specific subpopulations of patients known to be at high risk for poor PAC outcomes. These results will provide novel insights into the effect of MA plans on PAC use and outcomes, identifying potential benefits or unintended consequences that can shape policy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effect of post-acute care pay for performance in skilled nursing facilities on outcomes and disparities
  • 批准号:
    10365771
  • 项目类别:
  • 资助金额:
    $33.01万
  • 财政年份:
    2022
  • 负责人:
    Robert Edward Burke
  • 依托单位:
Effect of post-acute care pay for performance in skilled nursing facilities on outcomes and disparities
  • 批准号:
    10581532
  • 项目类别:
  • 资助金额:
    $58.96万
  • 财政年份:
    2022
  • 负责人:
    Robert Edward Burke
  • 依托单位:
Improving Post-Acute Care Value for Veterans
  • 批准号:
    10187950
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2021
  • 负责人:
    Robert Edward Burke
  • 依托单位:
Use of post-acute care and outcomes among Medicare Advantage and fee-for-service beneficiaries
  • 批准号:
    10390350
  • 项目类别:
  • 资助金额:
    $34.11万
  • 财政年份:
    2021
  • 负责人:
    Robert Edward Burke
  • 依托单位:
国内基金
海外基金
基于可见光环化反应的Post-Iboga类吲哚生物碱不对称集群合成
  • 批准号:
    22361048
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    32万元
  • 批准年份:
    2023
  • 负责人:
    潘志强
  • 依托单位:
盐皮质激素受体抑制2型固有淋巴细胞活化加重心肌梗死后心室重构的作用机制
  • 批准号:
    82372202
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    侯旭敏
  • 依托单位:
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
  • 批准号:
    82371738
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郑英霞
  • 依托单位:
基于菌群-肠-脑轴研究TMAO通过POST1/SREBP2调节星形胶质细胞胆固醇代谢参与针刺减轻糖尿病认知功能障碍的机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    王强
  • 依托单位: